Bli medlem
Bli medlem

Du är här


Omnicare: Omnicare Announces Conversion Rate Adjustment for Convertible Notes; Series A and Series B Trust PIERS to Accrue Contingent Interest

CINCINNATI, March 27, 2015
- Omnicare, Inc. (NYSE: OCR) (the "Company") announced today an adjustment to
the conversion rate of its 3.75% Convertible Senior Subordinated Notes due
2025 (the "2025 Notes"). Effective March 10, 2015, the adjusted conversion
rate for the 2025 Notes is 37.6440 shares of common stock per $1,000
principal amount, or approximately $26.56 per share.

The conversion rate for the 2025 Notes was previously 37.2532 shares of common
stock per $1,000 principal amount and was adjusted in connection with the
Company's regular quarterly dividend of $0.22 per share paid on March 27,
2015 to all stockholders of record on March 12, 2015.

Omnicare also announced that, for the period from March 15, 2015 to June 14,
2015, its Series A and Series B Trust Preferred Income Equity Redeemable
Securities (NYSE: OCR.PRA and OCR.PRB) (the "Trust PIERS") will, subject to
the terms of the Trust PIERS, accrue contingent interest at a rate of 0.125%
of the average trading price of the Trust PIERS for the five trading days
ended March 12, 2015, in addition to the continued accrual of regular cash
interest. As previously announced, the Trust PIERS have accrued and paid
contingent interest (ranging from $0.07 to $0.11 per $50 stated liquidation
amount of Trust PIERS) for each quarterly interest period since June 2013.

Contingent cash interest, which Omnicare has determined to be approximately
$0.1148 per $50 stated liquidation amount of Trust PIERS for the current
interest period, will be payable to holders of the Trust PIERS as of the
record date of June 12, 2015. The payment of contingent cash interest is
expected to be made on June 15, 2015.

About Omnicare

Omnicare, Inc., a Fortune 500 company based in Cincinnati, Ohio, provides
comprehensive pharmaceutical services to patients and providers across the
United States. As the market leader in professional pharmacy, related
consulting and data management services for skilled nursing, assisted living
and other chronic care institutions, Omnicare leverages its unparalleled
clinical insight into the geriatric market along with some of the industry's
most innovative technological capabilities to the benefit of its long-term
care customers. Omnicare also provides specialty pharmacy and key
commercialization services for the bio-pharmaceutical industry through its
Specialty Care Group. For more information,

# # #


Patrick C. Lee
(513) 719-1507


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Omnicare via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.